Novo Nordisk today announced the decision to re-initiate the global phase 3 development program of liraglutide for the treatment of obesity.
Following the US approval of Victoza for the treatment of type 2 diabetes, Novo Nordisk has been in dialogue with the FDA regarding the further progression of the development program investigating the potential of liraglutide within obesity. Based on the feedback from the FDA, Novo Nordisk now plans to re-initiate the global phase 3 program in the first half of 2011 in clinical trials comprising approximately 5,000 patients.
Novo Nordisk remains committed to the development of a longer-acting GLP-1 analogue and now expects to outline the clinical development strategy for semaglutide, a once-weekly GLP-1 analogue, and the once-weekly version of liraglutide in the second half of 2011.
